Comparison of the incidence of nausea and vomiting between linezolid and vancomycin using claims database: a retrospective cohort study

Tsutsumi, Takezo; Imai, Shungo; Momo, Kenji; Kashiwagi, Hitoshi; Sato, Yuki; Sugawara, Mitsuru; Takekuma, Yoh

Comparison of the incidence of nausea and vomiting between linezolid and vancomycin using claims database: a retrospective cohort study

Tsutsumi, Takezo; Imai, Shungo; Momo, Kenji et al.

International Journal of Clinical Pharmacy, 2023, 46, 421-428

Permalink : https://hdl.handle.net/2115/94055

このアイテムのアクセス数:437件（2026-08-17 16:42 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
Manuscript for Minor Revision IJCP-D-23-00477	pdf	441 KB	124

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/94055
タイトル	Comparison of the incidence of nausea and vomiting between linezolid and vancomycin using claims database: a retrospective cohort study
著者	Tsutsumi, Takezo ; Imai, Shungo ; Momo, Kenji ; Kashiwagi, Hitoshi ; Sato, Yuki ; Sugawara, Mitsuru ; Takekuma, Yoh
著者名 Tsutsumi, Takezo
e-Rad_Researcher 40845070 著者名 Imai, Shungo
e-Rad_Researcher 30645552 著者名 Momo, Kenji
e-Rad_Researcher 60510609 著者名 Kashiwagi, Hitoshi
e-Rad_Researcher 00564981 著者名 Sato, Yuki
e-Rad_Researcher 60332467 著者名 Sugawara, Mitsuru
e-Rad_Researcher 00396293 著者名 Takekuma, Yoh
言語	英語
キーワード	Adverse drug reaction
	Linezolid
	Nausea and vomiting
	Vancomycin
発行日	2023-12-29
出版者	Springer
収録物名	International Journal of Clinical Pharmacy
巻(号)	46
ページ	421-428
抄録	Background Nausea and vomiting during linezolid therapy have been reported as part of safety analyses in clinical trials. We have previously examined the incidence of vomiting during linezolid therapy (18.1%). A previous study conducted at a single hospital showed low external validity. It is necessary to verify whether these results can be reproduced using generalizable data sources.Aim To evaluate the incidence of nausea and vomiting during linezolid therapy compared with vancomycin using a Japanese claims database.Method Patients administered linezolid or vancomycin were selected from the database between January 2005 and June 2017. The primary endpoint was the comparison of nausea and vomiting between the linezolid and vancomycin groups. We conducted propensity score matching (PSM) to adjust for patient characteristics. To assess risk factors for nausea and vomiting, logistic regression was conducted as the secondary endpoint. We defined nausea and vomiting as the first prescription of antiemetics during linezolid or vancomycin therapy as a surrogate endpoint.Results In total, 1215 patients were enrolled. After PSM, the number of patients in the linezolid and vancomycin groups was 241. Nausea and vomiting were observed in 11.2% and 5.0% of patients in the linezolid and vancomycin groups, respectively (p < 0.05). Linezolid administration was extracted as a risk factor for nausea and vomiting (odds ratio, 2.09; 95% confidence interval, 1.02-4.30).Conclusion This study clarified the relationship between linezolid and nausea and vomiting using a Japanese claims database. Further studies are required to elucidate the unknown mechanisms of linezolid-induced nausea and vomiting.
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
権利情報	This version of the article has been accepted for publication, after peer review and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: http://dx.doi.org/10.1007/s11096-023-01668-9
PISSN	2210-7703
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.1007/s11096-023-01668-9